 PETAH TIKVA, Israel, Sept. 13, 2021 GLOBE NEWSWIRE -- PolyPid Ltd. Nasdaq: PYPD, a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced positive preclinical data in two key Glioblastoma Multiform GBM animal models of its OncoPLEX intra-tumoral cancer therapy program. 